Patient-derived cell models for personalized medicine approaches in cystic fibrosis is a research paper published in Journal of Cystic Fibrosis (2022). On theSindex it has a DataRank of 0. It has been cited 35 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: P30DK065988
Fondazione per la Ricerca sulla Fibrosi Cistica
Grant: 1/2020
Fondazione per la Ricerca sulla Fibrosi Cistica
Grant: 7/2013
Fondazione per la Ricerca sulla Fibrosi Cistica
Grant: FFC#9/2020
KU Leuven
Grant: 3M210333
King Baudouin Foundation
Grant: 2020-J1810150-217924
Cystic Fibrosis Foundation
Grant: CFF 001713G220
Cystic Fibrosis Foundation
Grant: GENTZS18P0
Cystic Fibrosis Foundation
Grant: GENTZS19I0
Cystic Fibrosis Foundation
Grant: BOUCHE19R0
FWCI
4.09
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
Additional file 1 of L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients
Additional file 1 of L1077P CFTR pathogenic variant function rescue by Elexacaftor–Tezacaftor–Ivacaftor in cystic fibrosis patient-derived air–liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients